_1557388532154.png?format=webp&height=120&width=120){kind=logo}
Verve - About the company
Verve is an acquired company based in Cambridge (United States), founded in 2018 by Burt Adelman, J Keith Joung and Sekar Kathiresan. It operates as a Developer of gene-editing therapies for treating coronary artery disease. Verve has raised $216M in funding from investors like Google Ventures, Casdin Capital and Wellington. The company has 559 active competitors, including 203 funded and 134 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Beam Therapeutics.
Company Details
Developer of gene-editing therapies for treating coronary artery disease. The lead candidate VERVE-101 is designed to be a single-course in vivo liver gene editing treatment.targeting the PCSK9 gene for treating cardio vascular disease.
- Website
- vervetx.com
- Social
- Phone Number
- +1 **********
Key Metrics
Founded Year
2018
Location
Cambridge, United States
Stage
Acquired
Total Funding
$216M in 3 rounds
Latest Funding Round
Investors
Ranked
15th among 559 active competitors
Employee Count
160 as on Jun 30, 2026
Exit Details
Acquired by Lilly (Jun 17, 2025)
Legal entities associated with Verve
Verve is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Verve Therapeutics, Inc. CIN: 1840574 , United States, Active | Mar 08, 2018 | - | - | - |
Verve Therapeutics, Inc. CIN: 82-4800132 , United States, Active | Mar 08, 2018 | - | 255 (As on Dec 31, 2023) | - |
Verve's acquisition details
Verve got acquired by Lilly on Jun 17, 2025.
Click here to take a look at Verve's acquisition in detail
Sign up to download Verve's company profile
Verve's funding and investors
Verve has raised a total funding of $216M over 3 rounds. Its first funding round was on May 07, 2019. Its latest funding round was a Series B round on Jan 19, 2021 for $*****. 12 investors participated in its latest round. Verve has 16 institutional investors.
Here is the list of recent funding rounds of Verve:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 19, 2021 | 3325420 | Series B | 3550132 | 4866332 | 2990858 | 4959026 |
Jun 11, 2020 | 1456502 | Series A | 2848148 | 9814080 | 9396884 | |
May 07, 2019 | 1102380 | Series A | 6911978 | 7511874 |
Access funding benchmarks and valuations. Sign up today!View details of Verve's funding rounds and investors
Verve's founders and board of directors
Founder? Claim ProfileHere are the details of Verve's key team members:
- Burt Adelman: Co-Founder & Chairman of Verve and founder of 1 other company.
- J Keith Joung: Co-Founder of Verve.
- Sekar Kathiresan: Founder & CEO of Verve.
View details of Verve's Founder profiles and Board Members
Verve's employee count trend
Verve has 160 employees as of Jun 26. Here is Verve's employee count trend over the years:
Uncover Verve's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Verve's Competitors and alternates
Top competitors of Verve include Alnylam, Spark Therapeutics and Beam Therapeutics. Here is the list of Top 10 competitors of Verve, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
3rd |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 71/100 | |
4th |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
5th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 70/100 | |
6th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
7th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
8th |  Generation Bio 2016, Cambridge (United States), Acquired | Developer of gene therapies for rare liver and eye diseases | $236M | 69/100 | |
9th | ElevateBio 2018, Cambridge (United States), Series D | Provider of transnational research for portfolio of cell and gene therapy | $1.25B | 68/100 | |
10th | Krystal Biotech 2015, Pittsburgh (United States), Public | Developer of genetic medicines to treat rare diseases | $11.3M | 67/100 | |
15th | _1557388532154.png?devicePixelRatio=2&height=30&width=30){kind=logo} Verve 2018, Cambridge (United States), Acquired | Developer of gene-editing therapies for treating coronary artery disease | $216M | 66/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Verve's competitors? Click here to see the top ones
Verve's Investments and acquisitions
Verve has made no investments or acquisitions yet.
Reports related to Verve
Here is the latest report on Verve's sector:
News related to Verve
Filter this listMedia has covered Verve for a total of 3 events in the last 1 year, 2 of them have been about company updates.
•
•
Eli Lilly and Company Completes Acquisition of Verve Therapeuticsintelligence360•Aug 05, 2025•Verve, Lilly, Steward Partners Global Advisory
•
Lilly Completes Verve Therapeutics Acquisition, Advancing Cardiovascular TreatmentsPR Newswire•Jul 25, 2025•Lilly, Verve
•
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of InvestigationsBenzinga•Jun 27, 2025•Verve, Brodsky Smith
•
GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)MarketBeat•Jun 24, 2025•Verve, GAMMA Investing
•
Halper Sadeh LLC Investigates VERV, SAGE, CTLP, COLBPR Newswire•Jun 20, 2025•Verve, SAGE Therapeutics, Halper Sadeh, Supernus Pharmaceuticals and 3 others
•
Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of ShareholdersGlobeNewswire•Jun 20, 2025•Cantaloupe, Verve, Lilly, Halper Sadeh and 1 other
•
Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of ShareholdersGlobeNewswire•Jun 18, 2025•Volato, Cantaloupe, SAGE Therapeutics, Verve and 1 other
•
Notifying Investors of Investigations: Verve, Sage, Cantaloupe, VolatoBenzinga•Jun 17, 2025•Brodsky Smith, Verve, Lilly, SAGE Therapeutics and 5 others
•
Eli Lilly to acquire Verve Therapeutics for USD 1.3 billionMedical Dialogues•Jun 17, 2025•Lilly, Verve
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Verve
Explore our recently published companies
- Capitalsfb.com - 2018 founded, Unfunded company
- Specule - Delhi based, 2017 founded, Unfunded company
- Tech Hive Technologies - Rawalpindi based, 2017 founded, Unfunded company
- Wise Accelerate - Hanoi based, 2021 founded, Unfunded company
- AblyCon Global - Bengaluru based, 2014 founded, Unfunded company
- Civoya - 2025 founded, Unfunded company
